Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., June 2, 2017 Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreementto expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint... Read more